États-Unis · Plateformes & données · MarketBeat

Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

Publié par MarketBeat · États-Unis il y a 31 min

Braveheart Bio (NASDAQ:BRVE) presented one-year data from a small study of its experimental heart drug BHB-1893 and outlined plans for a fixed-dose trial, as the company advances…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

À lire aussi

Franklin (BEN) Q4 2026 Earnings Call Transcript

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Haiti PM says gang leader Mathias Saintil dead

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Strawberry Fields (STRW) Q3 2026 Earnings Call Transcript

Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

Partager

À lire aussi

Franklin (BEN) Q4 2026 Earnings Call Transcript

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Haiti PM says gang leader Mathias Saintil dead

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Strawberry Fields (STRW) Q3 2026 Earnings Call Transcript